alterations,drugs,approvedIndications,level,fdaLevel,levelAssociatedCancerType,levelExcludedCancerTypes,pmids,abstracts,description
['Y1003'],"[{'ncitCode': 'C88314', 'drugName': 'Tepotinib'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['16227611', '30885356', '15123609', '25971938', '11741535', '27343443', '25079552', '16397241']",[],"Tepotinib, capmatinib and crizotinib are MET tyrosine kinase inhibitors (TKIs) that are FDA-approved (capmatinib and tepotinib) or NCCN-listed (crizotinib) for use in patients with non-small cell lung cancers (NSCLC) harboring MET exon 14 skipping mutations. While it is well established in vitro that mutations at MET Y1003 abrogate Cbl-mediated ubiquitination and downregulation, the same mechanism by which exon 14 skipping mutations are transforming, Y1003 mutations are not exon 14 skipping and are therefore not covered by the FDA-approval or the NCCN-listing of MET TKIs. One patient with MET Y1003S-mutant NSCLC had a partial response upon treatment with crizotinib (PMID: 27343443, 30885356, 25971938, 15123609, 25079552, 16397241, 16227611, 11741535)"
['Y1003'],"[{'ncitCode': 'C90564', 'drugName': 'Capmatinib'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['16227611', '30885356', '15123609', '25971938', '11741535', '27343443', '25079552', '16397241']",[],"Tepotinib, capmatinib and crizotinib are MET tyrosine kinase inhibitors (TKIs) that are FDA-approved (capmatinib and tepotinib) or NCCN-listed (crizotinib) for use in patients with non-small cell lung cancers (NSCLC) harboring MET exon 14 skipping mutations. While it is well established in vitro that mutations at MET Y1003 abrogate Cbl-mediated ubiquitination and downregulation, the same mechanism by which exon 14 skipping mutations are transforming, Y1003 mutations are not exon 14 skipping and are therefore not covered by the FDA-approval or the NCCN-listing of MET TKIs. One patient with MET Y1003S-mutant NSCLC had a partial response upon treatment with crizotinib (PMID: 27343443, 30885356, 25971938, 15123609, 25079552, 16397241, 16227611, 11741535)"
['Y1003'],"[{'ncitCode': 'C74061', 'drugName': 'Crizotinib'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['16227611', '30885356', '15123609', '25971938', '11741535', '27343443', '25079552', '16397241']",[],"Tepotinib, capmatinib and crizotinib are MET tyrosine kinase inhibitors (TKIs) that are FDA-approved (capmatinib and tepotinib) or NCCN-listed (crizotinib) for use in patients with non-small cell lung cancers (NSCLC) harboring MET exon 14 skipping mutations. While it is well established in vitro that mutations at MET Y1003 abrogate Cbl-mediated ubiquitination and downregulation, the same mechanism by which exon 14 skipping mutations are transforming, Y1003 mutations are not exon 14 skipping and are therefore not covered by the FDA-approval or the NCCN-listing of MET TKIs. One patient with MET Y1003S-mutant NSCLC had a partial response upon treatment with crizotinib (PMID: 27343443, 30885356, 25971938, 15123609, 25079552, 16397241, 16227611, 11741535)"
